Suicide Clinical Trial - ED Treatment of Suicidal Patients With Ketamine

Status Withdrawn

Clinical Trial Summary

This study aims to determine if a single intravenous (IV) dose of ketamine given in the emergency department (ED) can provide a long term reduction in suicidal ideation, lower time to ED discharge, and increase discharge to home or voluntary treatment facilities all while being safe.

Clinical Trial Description

Suicide has risen to the 2nd leading cause of death in Americans aged 10 to 34, and is the10th leading cause of death overall. Globally, the World Health Organization estimates one person dies of suicide every 40 seconds. Despite its lethality, no recognized acute treatments for suicidality exist. Recently, ketamine, an N-methyl-D-aspartate (NMDA) receptor agonist, has been shown to rapidly reduce suicidality in small studies in psychiatric settings. However, most patients with acute suicidal thoughts are treated initially in Emergency Departments (EDs). Delays in treatment have both short and long term impacts on recovery as patients spend longer time frames in an actively suicidal state.

Identifying a rapid and effective treatment for suicidal ideation that can be administered in the ED would have a profound impact on the emergent management of patients with suicidal thoughts. Ketamine is an FDA approved medication that is commonly used in EDs for multiple indications. EDs have the familiarity, facilities and personnel to safely administer IV ketamine.

Ketamine is regularly used in EDs in high doses for procedural sedation in adults and children. It is also used in high doses as a sedative for acutely agitated patients. In low-doses ketamine is frequently used for its analgesic properties and is considered safe.

Ketamine has also been safely used in the pre-hospital setting. In a recent joint policy statement of the American College of Emergency Physicians recommended the use of low-dose ketamine for pain in control with a safety profile comparable to other intravenous analgesia such as morphine.

Use of Ketamine to rapidly reduce suicidality may facilitate a safe and faster transition of acutely suicidal patients to outpatient treatment. Such treatment potentially shortens these patients' ED and hospital lengths of stay. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03502551
Study type	Interventional
Source	University of California, Davis
Contact
Status	Withdrawn
Phase	Phase 2
Start date	April 1, 2019
Completion date	June 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04127292` - Impact of Clinician Virtual Human Interaction Training in Emotional Self-Awareness on Patients Suicidal Ideation and Suicide Crisis Syndrome	N/A
Recruiting	`NCT06079853` - Nurse Suicide: Physiologic Sleep Health Promotion Trial	N/A
Recruiting	`NCT05423483` - Developing an Intervention to Promote Lethal Means Safety in Suicidal Adolescents	Phase 2
Completed	`NCT03272048` - Identifying Effective Approaches to Counseling on Firearm Safety	N/A
Completed	`NCT05514587` - Meaning of Life Questionnaire (MLQ) in Patients Admitted to the Crisis Centre (MSVCAC)
Enrolling by invitation	`NCT05639426` - Preventing Youth Violence Through Building Equitable Communities	N/A
Completed	`NCT03703128` - Suicide in People Aged 45-60: A Case-control Psychological Autopsy Study
Completed	`NCT03646903` - Reducing Help-Seeking Stigma in Young Adults at Elevated Suicide Risk	N/A
Not yet recruiting	`NCT06349915` - A Pilot Evaluation of a Digital Peer Support Intervention for Suicidal Adolescents	N/A
Not yet recruiting	`NCT05558332` - Youth Nominated Support Team	N/A
Completed	`NCT02718248` - Ottawa Suicide Prevention in Men Pilot Study	N/A
Completed	`NCT02094898` - Ketamine for Depression and Suicide Risk	Phase 2
Completed	`NCT01360736` - A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans - Study 2 (SAFEMIL)	N/A
Completed	`NCT01594138` - Linguistic Characteristics of Suicidal Patients in the Emergency Department	N/A
Completed	`NCT02228044` - Alcohol, Suicide and HIV Prevention for Teens in Mental Health Treatment	N/A
Completed	`NCT00604097` - Preventing Youth Suicide in Primary Care: A Family Model	Phase 3
Completed	`NCT00387855` - An Evaluation of the SOS (Suicide Prevention) Program	N/A
Recruiting	`NCT03519802` - Evaluation of Cognitive Function in a Suicidal Crisis
Completed	`NCT05580757` - Pharmacists as Gate Keepers in Suicide Prevention: Needs of Pharmacists
Recruiting	`NCT03030924` - Wearable Suicidal Early Warning System for Adolescents

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

ED Treatment of Suicidal Patients With Ketamine Infusion

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms